392 related articles for article (PubMed ID: 29912922)
1. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Enomoto N; Izumi N
PLoS One; 2018; 13(6):e0198812. PubMed ID: 29912922
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
3. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
4. Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure.
Cheng TY; Lee PC; Chen YT; Chao Y; Hou MC; Huang YH
Sci Rep; 2020 Oct; 10(1):18375. PubMed ID: 33110117
[TBL] [Abstract][Full Text] [Related]
5. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
[TBL] [Abstract][Full Text] [Related]
6. Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Labenz C; Prenosil V; Koch S; Huber Y; Marquardt JU; Schattenberg JM; Galle PR; Weinmann A; Wörns MA
Dig Dis; 2018; 36(1):78-88. PubMed ID: 28675895
[TBL] [Abstract][Full Text] [Related]
7. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.
Lanza E; Masetti C; Messana G; Muglia R; Pugliese N; Ceriani R; Lleo de Nalda A; Rimassa L; Torzilli G; Poretti D; D'Antuono F; Politi LS; Pedicini V; Aghemo A;
PLoS One; 2020; 15(6):e0232371. PubMed ID: 32555707
[TBL] [Abstract][Full Text] [Related]
8. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Michitaka K; Deguchi A; Ishikawa T; Imai M; Ochi H; Joko K; Shimada N; Tajiri K; Hirooka M; Koizumi Y; Hiasa Y; Tanaka J
J Gastroenterol Hepatol; 2019 Jun; 34(6):1066-1073. PubMed ID: 30549320
[TBL] [Abstract][Full Text] [Related]
9. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
10. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis.
Kuo YH; Wu IP; Wang JH; Hung CH; Rau KM; Chen CH; Kee KM; Hu TH; Lu SN
Invest New Drugs; 2018 Apr; 36(2):307-314. PubMed ID: 28466374
[TBL] [Abstract][Full Text] [Related]
11. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam.
Nguyen TTH; Nguyen VH; Nguyen VH; Nguyen TL; Le VQ
Cancer Control; 2019; 26(1):1073274819865269. PubMed ID: 31364390
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
[TBL] [Abstract][Full Text] [Related]
13. Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
Naganuma A; Hoshino T; Suzuki Y; Uehara D; Kudo T; Ishihara H; Sato K; Kakizaki S; Yamada M; Takagi H
Acta Med Okayama; 2017 Aug; 71(4):291-299. PubMed ID: 28824184
[TBL] [Abstract][Full Text] [Related]
14. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.
Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Kochi T; Suetsugu A; Shiraki M; Shimizu M
Int J Mol Sci; 2015 Apr; 16(5):9612-24. PubMed ID: 25927582
[TBL] [Abstract][Full Text] [Related]
17. Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study.
Hatanaka T; Kakizaki S; Uehara D; Nagashima T; Ueno T; Namikawa M; Saito S; Hosonuma K; Suzuki H; Naganuma A; Takagi H; Sato K; Uraoka T
Intern Med; 2019 Jul; 58(13):1835-1844. PubMed ID: 30918170
[TBL] [Abstract][Full Text] [Related]
18. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Sohn W; Paik YH; Cho JY; Lim HY; Ahn JM; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
J Hepatol; 2015 May; 62(5):1112-21. PubMed ID: 25514557
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]